nach oben

Erschienen in:

01.09.2011 | Original Article

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

verfasst von: Joel M. Reid, Sarah A. Buhrow, Mary J. Kuffel, Lee Jia, Victoria J. Spanswick, John A. Hartley, David E. Thurston, Joseph E. Tomaszewski, Matthew M. Ames

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501, SG2000) has potent in vitro antiproliferative activity and in vivo antitumor activity associated with binding in the minor groove of DNA and formation of covalent interstrand DNA cross-links. The pharmacokinetics and in vitro metabolism of SJG-136 and as well as the feasibility of using the Comet assay to measure in vivo interstrand DNA cross-links, was assessed in the rat.

Methods

SJG-136 pharmacokinetics and pharmacodynamics were characterized in rats following single-dose administration of 15 and 50 μg/kg or multiple-dose administration of 25 μg/kg/day for 5 days. DNA damage was measured in peripheral blood mononuclear cells using the Comet assay. SJG-136 oxidative metabolism was characterized in rat liver microsomes.

Results

SJG-136 half-life, clearance and volume of distribution values were 9 min, 190 ml/min/m², and 1780 ml/m², respectively. SJG-136 did not accumulate in plasma during treatment with 25 μg/kg/day for 5 days. Treatment with SJG-136 produced the anticipated DNA interstrand cross-links, as well as DNA strand breaks, in rat PBMCs. Oxidative metabolism of SJG-136 in rat liver microsomes was catalyzed by CYP3A isoforms and produced a previously unreported monomeric metabolite.

Conclusions

Plasma concentrations of SJG-136 associated with pharmacological activity and in vitro antiproliferative activity were achieved with doses that were tolerated by rats. CYP3A isoforms are the predominant P450s catalyzing SJG-136 metabolism. The comet assay detects DNA damage in PBMCs from rats treated with SJG-136 and is being used in clinical trials to monitor in vivo lesions produced by SJG-136.

Gregson SJ, Howard PW, Jenkins TC, Kelland LR, Thurston DE (1999) Synthesis of a novel C2/C2^′-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity. J Chem Soc Chem Commun 9:797–798

Gregson SJ, Howard PW, Gullick DR, Hamaguchi A, Corcoran KE, Brooks NA, Hartley JA, Jenkins TC, Patel S, Guille MJ, Thurston DE (2004) Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8^′ ether-linked C2-exo-unsaturated pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) dimers. J Med Chem 47(5):1161–1174PubMedCrossRef

Thurston DE (1993) Advances in the study of pyrrolo[2, 1-c][1,4]benzodiazepine (PBD) antitumor antibiotics. In: Neidle S, Waring MJ (ed) Topics in molecular and structural biology: molecular aspects of anticancer drug-DNA interactions. The MacMillan Press Ltd., London, pp 54–88

Bose DS, Thompson AS, Ching J (1992) Rational design of a highly efficient irreversible DNA interstrand coss-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc 114:4939–4941CrossRef

Smellie M, Kelland LR, Thurston DE, Souhami RL, Hartley JA (1994) Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. Br J Cancer 70(1):48–53PubMedCrossRef

Walton MI, Goddard P, Kelland LR, Thurston DE, Harrap KR (1996) Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. Cancer Chemother Pharmacol 38(5):431–438PubMedCrossRef

Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, Gregson SJ, Thurston DE, Sausville EA (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Cancer Res 64(18):6700–6706PubMedCrossRef

Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 64(18):6693–6699PubMedCrossRef

Pepper CJ, Hambly RM, Fegan CD, Delavault P, Thurston DE (2004) The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Res 64(18):6750–6755PubMedCrossRef

10.

Smellie M, Bose DS, Thompson AS, Jenkins TC, Hartley JA, Thurston DE (2003) Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers. Biochem 42(27):8232–8239CrossRef

11.

Rahman KM, Thompson AS, James CH, Narayanaswamy M, Thurston DE (2009) The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links. J Am Chem Soc 131(38):13756–13766PubMedCrossRef

12.

Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, Cobb M, Gumbrell L, Begent RH, Hartley JA, Jodrell D (2009) Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 15(6):2140–2147PubMedCrossRef

13.

Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Wade Calcutt M, Rizvi NA (2010) A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 65(5):833–838

14.

Puzanov I, Lee W, Berlin JD, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Hartley JA, Chen AP, Rothenburg ML (2008) Final results of phase I and pharmacokinetic trial of SJG136 administered on a daily x 3 schedule. J Clin Oncol 26 (suppl):2504

15.

Wilkinson GP, Taylor JP, Shnyder S, Cooper P, Howard PW, Thurston DE, Jenkins TC, Loadman PM (2004) Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. Invest New Drugs 22(3):231–240PubMedCrossRef

16.

Spanswick VJ, Hartley JM, Ward TH, Hartley JA (1999) Measurement of drug-indcued DNA interstrand crosslinking using the single cell gel electrophoresis (Comet) assay. In: Brown B (ed) Cytotoxic drug resistance mechanisms, methods in molecular medcine. Humana Press, USA, pp 143–154CrossRef

17.

Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the “comet” assay. Radiat Res 122(1):86–94PubMedCrossRef

18.

Helma C, Uhl M (2000) A public domain image-analysis program for the single-cell gel-electrophoresis (comet) assay. Mutat Res 466(1):9–15PubMed

19.

Buhrow SA, Reid JM, Jia L, McGovern RM, Covey JM, Kobs DJ, Grossi IM, Ames MM (2006) LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). J Chromatogr B Analyt Technol Biomed Life Sci 840(1):56–62PubMedCrossRef

20.

Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17PubMedCrossRef

21.

Soucek P, Gut I (1992) Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22(1):83–103PubMedCrossRef

22.

Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 5(3):507–512PubMed

23.

Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100(1):224–229PubMedCrossRef

24.

Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D (2001) Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 84(12):1671–1676PubMedCrossRef

25.

Petrusek RL, Uhlenhopp EL, Duteau N, Hurley LH (1982) Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell. J Biol Chem 257(11):6207–6216PubMed

Titel: Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats
verfasst von: Joel M. Reid
Sarah A. Buhrow
Mary J. Kuffel
Lee Jia
Victoria J. Spanswick
John A. Hartley
David E. Thurston
Joseph E. Tomaszewski
Matthew M. Ames
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1517-4

Springer Medizin

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats